DBA 703

DoctorSpot LLC

Authors

Sai Amruth Linga, Gejo Franklin, FNU Rashmi, Vasavi Polineni, Sai Charan Madhu

Table of Contents

Page #

1. Introduction 3

2. Background 3

3. Vision 3

4. Executive Summary 4

5. Problems 5

6. Proposed Solutions 8

a. Goals and Objectives 9

b. Action Steps 9

c. Protocols 9

d. Resources 10

e. Definition terms 10

7. References 11

Introduction

Poverty and inability to provide are amongst the major global problems that keeps humanity from reaching their full potential. It was quite evident that the pandemic has affected millions of households – and elderly – every day. But could focusing on one problem help to solve the other? We wanted to find out whether programs designed to supply vaccines and PPE gear for targeted countries which would improve their economic performance, and therefore, give them a better chance of having a life.

Background

Supplying pharmacy products is defined by the U.S. Department of Health and Human Services (HHS), as a form of regular access to medical supplements and PPE because of one’s financial status. According to the Department’s report, approximately 0.3 percent of American households, or approximately 0.4 million people, who are working at hospitals have experienced a shortage of PPE gear during the peak of COVID-19 pandemic. Since HHS considers contractors as partners, to help them to strengthen the business of government, the company has taken this opportunity in providing the best services one can offer. As a contractor, the company follows strict acquisition policies and guidelines to meet program goals, objectives, and performance measures, as well as provide the public with openness about taxpayer-funded resources.

Vision

To reach out to geographic areas around the globe that needs any medical attention, covid or non- covid related. Channeling the Supply of Vaccines, PPE and other healthcare equipment using an ERM platform that is Algorithm based to help connect with different health institutions around the world.

Executive summary

Our organization is focused on Smart Health care IT solution around the globe with the touch on innovation, using AI to provide better health solutions to our Partners during these unprecedented times. The major products of this company are supplying PPE and medicines and vaccines for oncology, immunology, cardiology, neurology, and endocrinology. The company earns more than half of its revenue from the USA. The company is best known for preparing the first COVID-19 Vaccine named BioNtech. The American government has set a target to vaccinate every individual in the USA before its Independence Day 2021. Apart from that, the organization has developed a pneumococcal conjugate vaccine for the treatment of breast cancer and the treatment and prevention of stroke in people with nonvalvular atrial fibrillation. The company has been a major player in supplying PPE products and manufacturing COVID-19 vaccines. This company saw its growth after it started supplying COVID-19 vaccines. It played a vital role in the production of Covid vaccines and its associated PPE products for the USA.

At the present situation, this company is one of the largest suppliers for COVID-19 Vaccines named BioNtech. In March 2020 when the COVID-19 pandemic was at its peak, this company partnered with BioNTech to research and develop mRNA vaccines for the virus. The initial funding was sponsored by the US Operation Wrap Seed vaccine development program. Present CEO aims to keep this company out of politics by avoiding accepting any money from Operation Wrap Seed. There was a huge challenge of COVID-19 vaccine development in a truly short period. The organization took the challenge with a great gesture and by May 2020 they began their testing process. The vaccine development process was a huge task for the organization. The organization had to prepare well proved and tested vaccine and then proceed with the clinical trials of the vaccine on the general population volunteers. By end of May, the company injected the first vaccine into humans. This was the first phase of the clinical trials and there was a total of three clinical trials scheduled. Because of so many clinical trials, the vaccine development process that several years. This is because the candidates injected with the vaccine need to be monitored for several months for any side effects. Partners received a fast-track designation from the FDA to start phase 2 and 3 of the clinical trials before the phase 1 results were out. These trials were conducted on 30,000 people. After successful results in the trials, the vaccine was allowed b the world health organization to be injected into the people. The US government procured the vaccine at a rate of $39 for two doses. The company also had an agreement with the European Union to supply 200 million doses to the European countries.

Problems

a) Structure a team that takes virtuous decisions

The task force we envision should have a clear knowledge of what the organization stands for and attain personal benefits in terms of freedom and career. Leaders always know how to give their team the best and give their peers the freedom to make smart decisions and pursue unconventional ideas. For this to happen every member of the team should take an ethical or virtuous stand, and that means they not only make decisions that put them on a good note but also benefit the organization (Sennette, 2012). This is a deficiency that needs to be filled in so that the task force can function ethically, and teams remain motivated around the globe in the organization.  

There are teams or even individuals who perform their best to achieve personal goals, but sometimes personal goals are not necessarily aligned with company goals. These teams/individuals should have the ability to differentiate between them. A good leader hence comes into play to guide these decisions. Our organization is in the Healthcare IT or e-care, is more fragile than any other when it comes to data handling and giving service to people who need care. A self-beneficial decision can impact the organization in a negative way, which in turn may affect a person’s life.  

The information being acquired in a healthcare world is very delicate and the importance of security and technology is extremely high. Having said that, a virtuous team and structure is especially important in our organization. Being an Artificial Intelligence-based organization, it raises other questions, like “Who should have access to the AI-generated data and patient identities and how it should be handled?” The structure of the team relies on the foundation of communication and clarity, being transparent from the highest authority in the structure, all the way to the care seeker. Building a functional organizational structure with moral and ethical values is deemed significant. This helps the team to grow personally and align with the organization's goals, keeping ethics and morals. Having ways to measure virtuousness needs to be put in place, not that virtuousness can be built, but only to establish the team and the organization has the same virtuous ideas because virtuousness is the pursuit of eudaemonism (Cameron & Winn 2012).

b) Different approaches to be considered for team efficiency.

For team efficiency there are many approaches to consider. One of the most common one is weighing on team improvement metrics such as velocity, stories/ tasks committed versus completed in an given iteration. These metrics measure the effort and time required to complete given list of prioritized tasks and help better plan for our future milestones. Team efficiency can also be measured on extent of team ownership. The best leaders in any area of business understand the power of ownership and help the team make their own decisions and make them accountable for their work. Setting realistic goals and timelines; understanding the strengths and weaknesses of each team member is another approach to accelerate team efficiency. It is rightly said that high-performance teams could be blessing for the organization as the teams would be playing the key role in boosting the organizational growth as well as the productivity by carrying out the meetings for overcoming the barriers. The barriers occur due to the differences in the roles, approaches, qualification, attitude, professional aspirations, experience, and the backgrounds of the teams. For improving team efficiency, a work team should focus on achieving the goals within the workplace and these goals should be specific to the project defining the responsibilities of each department. The goals are to be presented clearly by the management or the responsibilities of the team with clear objectives (Kimble, 2010).

c) Importance of considering organizational virtuousness.

The concept of organizational virtuousness, describe some initial empirical studies of organizational virtuousness and its relationship to performance, and propose an explanation for some of these associations. The Concept of Organizational Virtuousness Organizational virtuousness does not refer to an all or nothing condition. Neither individuals nor organizations are completely virtuous or non-virtuous. Rather, virtuousness in and through organizations can be manifest as single individuals’ activities or as collective action, and characteristics of an organization’s culture or processes may enable or disable virtuous deeds.  

The structure of an organization, for example, is inherently neither virtuous nor non-virtuous since it does not necessarily have intrinsic positive or negative human impact. However, the structure of the firm, was designed in a way that the firm’s 10,000 employees are organized into small family groups, each with total responsibility for key decisions, hiring, purchasing, budgeting, etc. This structure was designed specifically to perpetuate flourishing interpersonal relationships, meaningful work, enhanced learning, and personal development among employees. The intended positive human effects of this unique structure illustrate one key aspect of virtuousness in organizations—positive human impact.

Proposed solutions.

a) Goals and objectives:

This company assures its COVID-19 vaccine to have an efficacy of 95% in preventing symptomatic COVID-19 disease. The vaccine was approved for its urgent use by December 2020. Therefore, as several European and Asian countries approved the vaccine, its major challenge was to manufacture such a huge order on time and to every country.

The USA government also has demanded the company to distribute all its dosage to the USA citizens first and then export it to other countries. Several other government policies to supply dosage to Latin American countries on preference have also put pressure on the company to increase its manufacturing capacity (Hossain et al., 2020).

b) Action steps:

As this is a major problem where it is tough to meet the heavy demands, several solutions can be applied to overcome this problem. This organization has been awarded a total of 300 million vaccine dosages by the USA government. The company holds a capacity of developing 100 million vaccines per month and holds an order of more than 3 billion doses from 91 countries. Thus, the basic step the company can start with is to ask the US government to help in setting up fast-track manufacturing centers to meet the high demands.

c) Protocols:

Since finding proper solution in this pandemic situation requires lot of efforts and resources and this company has developed vaccine which should be available to all people. Those 300 million doses ordered from the USA is including both first and the second dose. Also, there is a time gap between the first and the second dose. Thus, when the driver of the first dose is over, the organization can start with equal distributions of orders to other countries. Some countries like the UK can be given an increased number of doses because of its high population (Hossain et al., 2020).

Lastly, the organization can partner with other vaccine manufacturing companies by taking a fast-track production license from the government for that organization. The doses produced in the partner countries can be distributed to countries with less population but with the same name. This will ensure timely completion of the order and an early end to the pandemic.

d) Resources:

Resources play an important role in a project; we can address the resources required for the project during the leadership meetings. It contributes to various areas of the project like design, focus, budget, availability of resources and current workflow process, and how the medication reconciliation can be integrated effectively (Baker, Narine, and Leatt 1994).

Planning and prioritizing the physical resources need to be effectively accomplished that conspire the key function of an organization that accounts for the available resources in the system. To appropriate clinical support, managerial services, supply chain services we need to integrate appropriate physical resources, human resources, and technological resources. 

Financial resources must be balanced properly from the inputs to deliver the services more effectively. Three types of resource strategy have been recommended with success ratio, efficient use of available resources through better performance, ensure a close match between skills, scope, and functions, greater use of multiskilled personnel (Baker, Narine, and Leatt 1994).

e) Definition terms:

Design facility, healthcare system, health care technology assessment, pre-architectural medical functional program, Regionalization, Sustainability

References:

M. S. Hossain, G. Muhammad and N. Guizani, "Explainable AI and Mass Surveillance System-Based Healthcare Framework to Combat COVID-I9 Like Pandemics," in IEEE Network, vol. 34, no. 4, pp. 126-132, July/August 2020, doi: 10.1109/MNET.011.2000458.

Tanne J H, Hayasaki E, Zastrow M, Pulla P, Smith P, Rada A G et al. Covid-19: how doctors and healthcare systems are tackling coronavirus worldwide BMJ 2020; 368 :m1090 doi:10.1136/bmj.m1090